• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

AZD-7762 Hydrochloride

Product ID A9912
Cas No. 1246094-78-9
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $92.80 In stock
5 mg $160.80 In stock
10 mg $252.70 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

AZD-7762 is an inhibitor of checkpoint kinase (CHK) 1 that increases sensitivity to DNA-damaging compounds. AZD-7762 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for a variety of cancers. In breast cancer and ovarian cancer cells, AZD-7762 inhibits cellular proliferation. In animal models of breast cancer, AZD-7762 inhibits tumor growth and increases survival rates. This compound displays somewhat limited efficacy due to cardiac toxicity.

Product Info

Cas No.

1246094-78-9

Purity

≥98%

Formula

C17H19FN4O2S • HCl

Formula Wt.

398.88

Synonym

AZD-7762 HCl

Solubility

DMSO 50 mg/mL (137.96 mM) Water Insoluble Ethanol Insoluble

Appearance

White to off white powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

A9912 MSDS PDF

Info Sheet

A9912 Info Sheet PDF

References

Bryant C, Rawlinson R, Massey AJ. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer. 2014 Aug 7;14:570. PMID: 25104095.

Sausville E, Lorusso P, Carducci M, et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):539-49. PMID: 24448638.

Ma CX, Cai S, Li S, et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest. 2012 Apr;122(4):1541-52. Erratum in: J Clin Invest. 2012 Jul 2;122(7):2702. PMID: 22446188.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only